A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation. (NCI)

A human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose disease has not gotten better during or after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. ABX-EGF binds to the epidermal growth factor receptor (EGFR) and may block tumor cell growth.

Recombinant human monoclonal antibody that binds to and inhibits the function of the EPIDERMAL GROWTH FACTOR RECEPTOR. It is used in the treatment of EGFR-expressing metastatic colorectal cancer that expresses wild-type ras gene (see GENES, RAS).